InterventionsHuman trial
Safety, Tolerability, Pharmacokinetics (PK), and Pharmacodynamics (PD) of a Dual GLP-1/GIP Receptor Agonist (HDM1005)—A Phase I, Randomized, Double-Blind, Placebo-Controlled, Single and Multiple Dose-Escalation Study
ADA Scientific Sessions 2025 Abstract
The paper
DU Y, HU W, ZHANG Q et al.
ADA Scientific Sessions 2025 Abstract · 13 Jun 2025
Presented at ADA Scientific Sessions 2025 · Oral 142-OR